Radiofrequency thermal destruction in current treatment of liver malignancies. Literature review

Radiofrequency thermal destruction (thermoablation) remains one of the most popular methods of local destruction of liver tumors. There are perennial international experience in oncology, numerous trials and practical issues are rarely discussed. However, there are still strategic questions: when, to whom, in what cases. In fact, specialists recognizing effective impact do not always sure when thermoablation potential will be realized as much as possible. In this review the authors summarized world experience of liver malignancies thermoablation and tried to identify key positions in determining treatment strategy using this approach. Interdisciplinary approach is an absolute priority in optimal treatment of these patients.

[1]  Xiao-yan Xie,et al.  Combined radiofrequency ablation and ethanol injection versus repeat hepatectomy for elderly patients with recurrent hepatocellular carcinoma after initial hepatic surgery , 2018, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[2]  B. Luo,et al.  Insufficient radiofrequency ablation promotes proliferation of residual hepatocellular carcinoma via autophagy. , 2018, Cancer letters.

[3]  M. Abecassis,et al.  AASLD guidelines for the treatment of hepatocellular carcinoma , 2018, Hepatology.

[4]  H. Baba,et al.  Long‐term outcomes of radiofrequency ablation combined with hepatectomy compared with hepatectomy alone for colorectal liver metastases , 2017, The British journal of surgery.

[5]  N. Heaton,et al.  Breast cancer liver metastases in a UK tertiary centre: Outcomes following referral to tumour board meeting. , 2017, International journal of surgery.

[6]  Jin Won Lee,et al.  Radiofrequency ablation for liver metastases in patients with gastric cancer as an alternative to hepatic resection , 2017, BMC Cancer.

[7]  M. A. van den Bosch,et al.  The diagnostic performance of 18F-FDG PET/CT, CT and MRI in the treatment evaluation of ablation therapy for colorectal liver metastases: A systematic review and meta-analysis. , 2017, Surgical oncology.

[8]  Peihong Wu,et al.  Combined CT-guided radiofrequency ablation with systemic chemotherapy improves the survival for nasopharyngeal carcinoma with oligometastasis in liver: Propensity score matching analysis , 2016, Oncotarget.

[9]  Christophe Aubé,et al.  Comparison of no-touch multi-bipolar vs. monopolar radiofrequency ablation for small HCC. , 2017, Journal of hepatology.

[10]  Antônio Rahal,et al.  Percutaneous Cholecystostomy and Hydrodissection in Radiofrequency Ablation of Liver Subcapsular Leiomyosarcoma Metastasis Adjacent to the Gallbladder: Protective Effect. , 2016, Journal of radiology case reports.

[11]  Afshin Gangi,et al.  18F-FDOPA PET/CT-Guided Radiofrequency Ablation of Liver Metastases from Neuroendocrine Tumours: Technical Note on a Preliminary Experience , 2016, CardioVascular and Interventional Radiology.

[12]  Wei Yang,et al.  Ten-year survival of hepatocellular carcinoma patients undergoing radiofrequency ablation as a first-line treatment. , 2016, World journal of gastroenterology.

[13]  W. Lau,et al.  Randomized clinical trial of chemoembolization plus radiofrequency ablation versus partial hepatectomy for hepatocellular carcinoma within the Milan criteria , 2016, The British journal of surgery.

[14]  Kwang Hee Kim,et al.  Comparison of Hepatic Resection and Radiofrequency Ablation for the Treatment of Colorectal Liver Metastasis , 2015, Indian Journal of Surgery.

[15]  Xia Li,et al.  Radiofrequency ablation versus percutaneous ethanol injection for hepatocellular carcinoma: a meta-analysis of randomized controlled trials , 2015, World Journal of Surgical Oncology.

[16]  Shiyou Wei,et al.  Radiofrequency Ablation versus Hepatic Resection for Small Hepatocellular Carcinomas: A Meta-Analysis of Randomized and Nonrandomized Controlled Trials , 2014, PloS one.

[17]  Ling Zhang,et al.  Efficacy and safety of percutaneous radiofrequency ablation versus surgical resection for small hepatocellular carcinoma: a meta-analysis of 23 studies , 2014, Journal of Cancer Research and Clinical Oncology.

[18]  M. Pompili,et al.  Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma ≤3 cm. Results of a multicenter Italian survey. , 2013, Journal of hepatology.

[19]  Yao-ting Chen,et al.  Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma. , 2013, World journal of gastroenterology.

[20]  J. Ledermann,et al.  Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  Riccardo Lencioni,et al.  EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. , 2012, Journal of hepatology.

[22]  Gerlig Widmann,et al.  Percutaneous stereotactic radiofrequency ablation of colorectal liver metastases , 2012, European Radiology.

[23]  M. Milas,et al.  Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term follow-up. , 2010, Surgery.

[24]  T. de Baère,et al.  Combined liver surgery and RFA for patients with gastroenteropancreatic endocrine tumors presenting with more than 15 metastases to the liver. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[25]  Byung Soh Min,et al.  Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. , 2009, American journal of surgery.

[26]  M. Milas,et al.  Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. , 2007, Surgery.

[27]  E. Furth,et al.  Lack of benefit of pre‐transplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.